Ligand Pharmaceuticals (LGND) Profitability Boost From US$102.9m One Off Gain Tests Bull Case

Simply Wall St.02-28

Ligand Pharmaceuticals (LGND) has reported FY 2025 results with fourth quarter revenue of US$59.7 million and basic EPS of US$2.27, while trailing twelve month figures show revenue of US$268.1 million...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614381290?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-28 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614381290","market":"sg","top_or_hot":-1,"title":"Ligand Pharmaceuticals (LGND) Profitability Boost From US$102.9m One Off Gain Tests Bull Case","media":"Simply Wall St.","content":"<div>\n<p>Ligand Pharmaceuticals (LGND) has reported FY 2025 results with fourth quarter revenue of US$59.7 million and basic EPS of US$2.27, while trailing twelve month figures show revenue of US$268.1 million...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-profitability-boost-from-us1029m\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ligand Pharmaceuticals (LGND) Profitability Boost From US$102.9m One Off Gain Tests Bull Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLigand Pharmaceuticals (LGND) Profitability Boost From US$102.9m One Off Gain Tests Bull Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-profitability-boost-from-us1029m><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ligand Pharmaceuticals (LGND) has reported FY 2025 results with fourth quarter revenue of US$59.7 million and basic EPS of US$2.27, while trailing twelve month figures show revenue of US$268.1 million...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-profitability-boost-from-us1029m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0566484027.USD","symbol_name":"安本美国小盘成长股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-profitability-boost-from-us1029m","article_id":"2614381290","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/ligand-pharmaceuticals-lgnd-profitability-boost-from-us1029m","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614381290","pubTimestamp":1772285220,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ligand Pharmaceuticals (LGND) has reported FY 2025 results with fourth quarter revenue of US$59.7 million and basic EPS of US$2.27, while trailing twelve month figures show revenue of US$268.1 million and basic EPS of US$6.44. Over the past few quarters, the company has seen revenue move from US$42.8 million in Q4 2024 to US$45.3 million in Q1 2025, US$47.6 million in Q2 2025, US$115.5 million in Q3 2025 and US$59.7 million in Q4 2025, alongside basic EPS ranging from a loss of US$2.21 in Q1...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0566484027.USD":"安本美国小盘成长股","BK4139":"生物科技","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"Ligand Pharmaceuticals(LGND)盈利能力从1.029亿美元一次性收益增长测试牛市案例","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1.5},"content_text":"Ligand Pharmaceuticals (LGND) has reported FY 2025 results with fourth quarter revenue of US$59.7 million and basic EPS of US$2.27, while trailing twelve month figures show revenue of US$268.1 million and basic EPS of US$6.44. Over the past few quarters, the company has seen revenue move from US$42.8 million in Q4 2024 to US$45.3 million in Q1 2025, US$47.6 million in Q2 2025, US$115.5 million in Q3 2025 and US$59.7 million in Q4 2025, alongside basic EPS ranging from a loss of US$2.21 in Q1 2025 to US$5.99 in Q3 2025. This has set up a profit profile where margins now hinge on how sustainable this mix of recurring earnings and one off gains proves to be. See our full analysis for Ligand Pharmaceuticals. With the headline numbers on the table, the next step is to set these results against the widely followed narratives around growth, risks and quality of earnings to see which views hold up and which might need a rethink. See what the community is saying about Ligand Pharmaceuticals NasdaqGM:LGND Revenue & Expenses Breakdown as at Feb 2026 AdvertisementProfit swings tied to US$102.9m one off gain  Trailing twelve month net income of US$124.5 million and basic EPS of US$6.44 include a US$102.9 million one off gain that has a major impact on how strong the profit picture looks over the last year. What stands out for the bullish narrative is that the company is now profitable over the last 12 months, which lines up with expectations for stronger recurring royalty income. However, the heavy reliance on that US$102.9 million gain means investors still need to separate underlying earnings power from this single boost.\n     Consensus narrative talks about recurring, high margin royalties supporting long term cash flow, while the data shows quarterly net income ranging from a loss of US$42.5 million in Q1 2025 to a profit of US$117.3 million in Q3 2025. That wide range plus the one off item can support optimism about the model working, but it also means bulls have to account for the fact that recent profitability is not yet a simple, steady trend.    From losses to US$124.5m profit in a year  On a trailing basis, net income moved from a loss of US$132.6 million at the start of FY 2025 to a profit of US$124.5 million by Q4 2025, while the five year earnings trend in the analysis data still points to an average 12.7% annual decline. Bears focus on that five year earnings decline and the dependence on a handful of royalty assets, and the quarterly pattern in 2025, with losses in Q1 and modest profit in Q2 before a very strong Q3, gives them numbers to point to as they question how smooth that earnings path can be.\n     The bearish narrative highlights concentration in assets like O2vir and Filspari, and the swing from a loss of US$31.1 million in Q4 2024 to a profit of US$44.8 million in Q4 2025 underlines how sensitive results can be to a small set of drivers. At the same time, the move into profitability over the last year challenges the idea that the business cannot generate positive earnings, so the bear case leans more on durability and concentration risk than on current loss making operations.    Investors who want to see how optimistic analysts connect these profit swings to future royalty streams can dig into the detailed bull case for Ligand Pharmaceuticals here: 🐂 Ligand Pharmaceuticals Bull Case Premium P/E with mixed signals on value  The stock trades on a trailing P/E of about 31.4x at a share price of US$198.31, compared with peer and US pharmaceuticals industry averages near 20x. The analysis data also shows a DCF fair value of roughly US$282.86 and an analyst price target of US$244.33, both higher than the current price. Critics argue that paying a premium P/E multiple for a company whose recent earnings include a US$102.9 million one off gain is risky, and the tension in the data is that the same model set pointing to higher fair value also flags that a lot of the recent EPS strength is not purely from recurring operations.\n     Rewards in the summary mention earnings forecast growth of about 12.6% a year and revenue forecast growth of about 10.6% a year, which helps explain why the market is willing to sit above peer multiples. At the same time, the higher P/E and the five year earnings decline of 12.7% a year give bears a concrete argument that a full re rating may depend on cleaner, less one off heavy profitability over time.    Skeptical readers who see a 31.4x P/E and one off heavy earnings may want to study how the more cautious narrative interprets these same numbers: 🐻 Ligand Pharmaceuticals Bear Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Ligand Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. If this mix of bull and bear arguments leaves you undecided, now is a good time to look through the numbers yourself and stress test your own thesis. You can start with 4 key rewards and 2 important warning signs. See What Else Is Out There Ligand Pharmaceuticals relies heavily on a US$102.9 million one off gain and a narrow set of royalty assets, with a five year earnings decline of 12.7% a year. If that concentration risk and earnings volatility worry you, take a few minutes to scan our 77 resilient stocks with low risk scores and compare steadier business profiles side by side.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614381290","isCrawlerRequest":true}